Successful extension of tocilizumab infusion intervals from 4 weeks to 5 or 6 weeks in 90% of rheumatoid arthritis patients with good response to 4-week intervals

Clinical and Experimental Rheumatology

Volumn 35, Issue 4, 2017, Pages 666-670

  Saiki, Osamu ^a,b   Uda, Hiroshi ^a  

^a Higashiosaka City General Hospital   (Japan)

^b Diabetes Center   (Japan)

Author keywords

Extension of intervals; Rheumatoid arthritis; Tocilizumab

Indexed keywords

METHOTREXATE; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85028668132     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. McINNES IB, SCHETTS G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19
2. FURST DE, EMERY P: Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 2014; 53: 1560-9
3. AKIRA S, HIRANO T, TAGA T, KISHIMOTOK T: Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990; 4: 2860-7
4. NISHIMOTO N, TERAO K, MIMA T, NAKAHARA H, TAKAGI N, KAKEHI T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64
5. NISHIMOTO N, HASHIMOTO J, MIYASAKA N et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7
6. GENOVESE MC, McKAY JD, NASONOVN EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying anti-rheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80
7. DOUGADOSD M, KISSEL K, SHEERAN T et al.: Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72: 43-50
8. SINGH JA, BEG S, LOPEZ-OLIVO MA: Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38: 10-20
9. ROSHE REGISTRATION LIMITED: RoACTEMRA 20 mg/ml concentrate for solution for infusion. Welwyn Garden City, UK: Roshe Registration Limited, 2012
10. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81
11. FRANSEN J, CREEMERS MC, Van RIEL PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5
12. UDA H, SAIKI O: Appearance of non-rheumatoid arthralgia after tocilizumab treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2013; 42: 247-8
13. UDA H, YOKOTA A, KOBAYASHI K et al.: Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 2006; 33: 1482-7
14. OGATA A, TANIMURA K, SUGIMOTO T et al.: Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 2014; 66: 344-54
15. KAMEDA H, AMANO K, NAGASAWA H et al.: Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod Rheumatol 2004; 14: 442-6